Applied DNA Sciences (FRA:UDJ) EBIT : €-13.35 Mil (TTM As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Applied DNA Sciences EBIT?

Applied DNA Sciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was €-3.33 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was €-13.35 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Applied DNA Sciences's annualized ROC % for the quarter that ended in Mar. 2024 was -257.29%. Applied DNA Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -960.75%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Applied DNA Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7,376.24%.

Applied DNA Sciences EBIT Historical Data

The historical data trend for Applied DNA Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied DNA Sciences EBIT Chart

Applied DNA Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT

Get a 7-Day Free Trial

-7.68

-10.64

-10.65

-14.11

-10.26

Applied DNA Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-2.53	-2.64	-3.91	-3.48	-3.33

Competitive Comparison of Applied DNA Sciences's EBIT

For the Diagnostics & Research subindustry, Applied DNA Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied DNA Sciences's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Applied DNA Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Applied DNA Sciences's EV-to-EBIT falls into.

Applied DNA Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.35 Mil.

Applied DNA Sciences (FRA:UDJ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Applied DNA Sciences's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-13.316 * ( 1 - 0% )	/	( (5.398	+	4.953)	/ 2 )
=	-13.316	/	5.1755
=	-257.29 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.09	-	1.856	-	( 3.08	-	max(0, 2.373	-	4.209	+	3.08	))
=	5.398

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.442	-	1.886	-	( 2.898	-	max(0, 2.413	-	4.016	+	2.898	))
=	4.953

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Applied DNA Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-13.316	/	( ( (1.519 + max(-0.776, 0))	+	(1.253 + max(-0.815, 0)) )	/	2 )
=	-13.316	/	( ( 1.519	+	1.253 )	/	2 )
=	-13.316	/	1.386
=	-960.75 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.414	+	0.346	+	0.369)	-	(1.856	+	0.05	+	-0.00099999999999989)
=	-0.776

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.376	+	0.309	+	0.433)	-	(1.886	+	0.047	+	0)
=	-0.815

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Applied DNA Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-13.351	/	-0.181
	=	7,376.24 %

Applied DNA Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Applied DNA Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied DNA Sciences (FRA:UDJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Applied DNA Sciences Inc (FRA:UDJ) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

APDN:USA UDJP:Germany

Address

50 Health Sciences Drive, Stony Brook, New York, NY, USA, 11790

Website

https://www.adnas.com

Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

Applied DNA Sciences (FRA:UDJ) Headlines

No Headlines